The past decade witnessed an increasing role for GLP-1 agonists in the management of metabolic disorders, including DM, obesity, and metabolic-dysfunction-associated steatohepatitis (MASH), as well as cardio-renal protective effects. The gene discussed is GLP1R; the disease is obesity disorder.